Related Experiment Videos
Immunologic changes in renal cell carcinoma patients receiving gamma interferon
B P Barna1, M J Thomassen, J Sergi
1Department of Immunopathology, Cleveland Clinic Foundation, Ohio.
Oncology
|January 1, 1991
Summary
Recombinant interferon gamma (rIFN gamma) showed potential in enhancing immune function for metastatic renal cell carcinoma patients. Immunologic activity increased, with minimal toxicity, suggesting rIFN gamma may be a useful therapeutic agent.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Metastatic renal cell carcinoma (mRCC) presents significant treatment challenges.
- Immunotherapy is an emerging strategy for mRCC.
- Recombinant interferon gamma (rIFN gamma) is being investigated for its immunomodulatory effects.
Purpose of the Study:
- To evaluate the immunologic effects of recombinant interferon gamma (rIFN gamma) in patients with metastatic renal cell carcinoma.
- To assess the safety and potential efficacy of rIFN gamma in this patient population.
Main Methods:
- A phase II clinical trial involving 5 patients with mRCC.
- Intravenous administration of rIFN gamma at two different dose regimens over 4 weeks.
- Monitoring of immunologic parameters including natural killer (NK) cell activity, monocyte-mediated tumoricidal activity, and prostaglandin E2 synthesis.
Main Results:
- One minor treatment response observed at the higher rIFN gamma dose.
- Minimal toxicity (grades I-II) reported.
- Significant increases in natural killer cytolytic activity and spontaneous monocyte-mediated tumoricidal activity.
- Reduction in elevated prostaglandin E2 synthesis by patient leukocytes during treatment.
Conclusions:
- Recombinant interferon gamma (rIFN gamma) demonstrated immunomodulatory effects in mRCC patients.
- rIFN gamma may enhance immune function relevant to cancer control.
- Further investigation is warranted to explore the therapeutic potential of rIFN gamma in renal cell carcinoma.